Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case-time-control design

S Suissa1

  • 1Department of Epidemiology and Biostatistics, McGill University, Quebec, Canada.

Epidemiology (Cambridge, Mass.)
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

The case-time-control design reduces confounding by indication when assessing drug effects. This method found inhaled beta-agonist use had minimal association with fatal asthma risk, challenging previous beliefs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioglitazone and bladder cancer: improving research methods.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

A systematic review of observational studies of the association between pioglitazone use and bladder cancer.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.

BJOG : an international journal of obstetrics and gynaecology·2017
Same author

Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study.

BJOG : an international journal of obstetrics and gynaecology·2016
Same author

Concern on quality-of-life analysis in the OPTIMAL study.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same journal

Application of the E-value under non-proportional hazards.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Can the All of Us sample be reweighted to mirror a nationally representative sample? A comparison of mortality predictors.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Gut health, systemic inflammation, and linear growth among Indonesian infants: findings from the Action Against Stunting Hub observation cohort: Erratum.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Evaluating Estimators in Partially Identified Models.

Epidemiology (Cambridge, Mass.)·2026
Same journal

Stratification and accumulation? Explaining changing mortality inequities between business owners and non-owners in the U.S. (1984-2022).

Epidemiology (Cambridge, Mass.)·2026
Same journal

Be wary of age-stratum aging in early-onset cancer trends.

Epidemiology (Cambridge, Mass.)·2026
See all related articles

Area of Science:

  • Epidemiology
  • Pharmacovigilance
  • Biostatistics

Background:

  • Assessing drug effects using observational studies is challenging due to confounding by indication, where disease severity influences both drug prescription and outcomes.
  • Accurate measurement of disease severity is often lacking in traditional epidemiologic designs, limiting the ability to isolate true drug effects.
  • Confounding by indication poses a significant barrier to understanding the true risks and benefits of medications in real-world settings.

Purpose of the Study:

  • To introduce and validate the case-time-control design as a novel method to overcome confounding by indication in drug safety studies.
  • To estimate the association between inhaled beta-agonist use and the risk of fatal or near-fatal asthma, adjusting for unmeasured disease severity.
  • To re-evaluate the role of beta-agonists in asthma mortality using a design that accounts for disease severity.

Related Experiment Videos

Main Methods:

  • Proposed the case-time-control design, which utilizes subjects as their own controls, requiring exposure data at multiple time points.
  • Developed a logistic regression model to estimate relative risks within the case-time-control framework.
  • Applied the design to a case-control study of 129 fatal/near-fatal asthma cases and 655 controls, examining inhaled beta-agonist use.

Main Results:

  • The conventional case-control analysis yielded a relative risk of 3.1 (95% CI = 1.8-5.4) for high vs. low beta-agonist use, reflecting confounding by indication.
  • The case-time-control design produced a relative risk estimate of 1.2 (95% CI = 0.5-3.0), effectively removing the confounding effect of unmeasured disease severity.
  • Dose-response analyses suggested a potential association only at excessive doses of beta-agonists.

Conclusions:

  • The case-time-control design successfully mitigates confounding by indication, providing a less biased estimate of drug effects.
  • The findings suggest that inhaled beta-agonists may not be the primary driver of fatal or near-fatal asthma risk, contrary to prior suspicions.
  • Further investigation into excessive beta-agonist use is warranted to fully understand their role in severe asthma exacerbations.